Mihai Sorin Iacob

Dr. Mihai Sorin Iacob

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2024 in Primary Health Care Research & Development
Verified
Journal Article
Open access
PDF file
APAaron Poppleton
Aaron Poppleton
STSonia Tsukagoshi
Sonia Tsukagoshi
SVShlomo Vinker
Shlomo Vinker
FHFrancois Heritier
Francois Heritier
PFPaul Frappé
Paul Frappé
DHDavid Halata
David Halata

14 May 2025 in Life
Verified
Journal Article
Open access
PDF file
MIMihai Sorin Iacob
Mihai Sorin Iacob
Nilima Rajpal KundnaniNilima Rajpal Kundnani
Nilima Rajpal Kundnani
ASAbhinav Sharma
Abhinav Sharma
VMVlad Alexandru Meche
Vlad Alexandru Meche
PCPaul Gabriel Ciubotaru
Paul Gabriel Ciubotaru
LSLivia Claudia Stanga
Livia Claudia Stanga
Background: Heart failure (HF), chronic kidney disease (CKD), and atrial fibrillation (AF) frequently coexist, forming a high-risk triad that amplifies morbidity and mortality through shared pathophysiological mechanisms such as neurohormonal activation, fluid overload, and inflammation. Current risk stratification tools, including CHA2DS2-VASc and HAS-BLED, inadequately capture the complexity of these multimorbid patients. This study aims to explore the influence of comorbidities, hypertension severity, anticoagulation strategy, and risk scores on hospitalization outcomes in patients with coexisting HF, CKD, and AF. Materials and Methods: A retrospective case study was conducted on 174 hospitalized patients with HF, CKD, and AF. Clinical data included hypertension grade, HF phenotype (HFpEF vs. HFrEF), NYHA classification, renal function (KDIGO stage), stroke and bleeding risk scores (CHA2DS2-VASc: congestive heart failure, hypertension, age ≥ 75, diabetes, and stroke/TIA; HAS-BLED: hypertension, abnormal renal/liver function, stroke, bleeding, labile INR, elderly, and drugs/alcohol), comorbidities (neurological, psychiatric, COPD, and diabetes), anticoagulation type (DOACs vs. VKAs), and length of hospital stay. Statistical analysis included Spearman correlation, independent t-tests, and multivariate regression to evaluate associations between variables and clinical outcomes. Results: Most patients were elderly (mean age 75 ± 12), with advanced CKD (stage 3b) and systolic HF (77% HFrEF). Mean CHA2DS2-VASc was 5.67, HAS-BLED was 4.40, and ATRIA was 4.74, indicating high stroke and bleeding risk. Anticoagulation was predominantly via DOACs (69.5%). Hypertension severity did not significantly correlate with NYHA class (ρ = −0.14, p = 0.068). Neurological, psychiatric, and metabolic comorbidities showed no significant associations with HF severity. COPD and diabetes correlated inversely with CHA2DS2-VASc scores (ρ = −0.83, p = 0.014). No significant differences were observed in hospital stay between HF phenotypes or prior stroke history. In-hospital mortality was low (2.3%). Conclusions: Traditional risk scores do not fully capture the complexity of multimorbid patients. Metabolic comorbidities showed an inverse correlation with stroke risk scores, and no significant correlation was observed between hypertension severity and HF symptom burden. Hypertension and common comorbidities did not correlate with HF symptom burden, and metabolic diseases may paradoxically associate with lower stroke risk scores. These findings highlight the need for improved multimodal risk assessment strategies that consider the heterogeneity of multimorbid populations. Personalized, integrated approaches are essential to optimize anticoagulation, reduce hospitalization, and improve prognosis.

6 September 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Nilima Rajpal KundnaniNilima Rajpal Kundnani
Nilima Rajpal Kundnani
CLCodrina Levai
Codrina Levai
MPMihaela-Diana Popa
Mihaela-Diana Popa
CBClaudia BORZA
Claudia BORZA
MIMihai Sorin Iacob
Mihai Sorin Iacob
ABAlexandru Iulian Ciprian Blidisel
Alexandru Iulian Ciprian Blidisel
Introduction: Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder characterized by significant autoantibodies, particularly targeting nuclear antigens. SLE pathogenesis involves genetic, environmental, and hormonal factors. The disease course includes flares and remission and involves various organs. Recent therapeutic progresses, including biologics, have improved management and prognosis, though the long-term impact of novel therapies remains to be determined. Biologics in SLE: Rituximab, the earliest B-cell-oriented biologic, binds CD20 and depletes CD20+ B cells, leading to remission in some SLE patients. Belimumab is a B-cell-activating factor (BAFF) inhibitor with a recent additional indication for lupus nephritis. The CALIBRATE and BLISS-BELIEVE studies investigated combinations of these drugs with conventional therapies, showing varied efficacy. Ocrelizumab and obinutuzumab, newer CD20-oriented SLE therapies, together with ofatumumab and veltuzumab, are also promising. The latest trials highlight their efficacy and safety. Anifrolumab, targeting type-I interferon receptors, was evaluated in the TULIP 1/2 trials. The ongoing TULIP LTE trial supports the long-term safety and efficacy of anifrolumab. Additionally, the IRIS Phase III trial is exploring anifrolumab for lupus nephritis, showing favorable renal responses. Tocilizumab and secukinumab are being assessed for SLE, with mixed outcomes. Several biologics targeting the C5 complement protein, together with immunomodulators and immunotherapeutics, are also under investigation for potential benefits in SLE. Discussion: Biologics in SLE target specific immune components, aiming to improve disease control and reduce the side effects of conventional therapy. However, trial outcomes vary due to factors like inclusion criteria and trial design. Conclusions: Biotechnology progress enables targeted biologic therapies for SLE, reducing disease activity and improving patients’ quality of life.

16 June 2025 in Life
Verified
Journal Article
Open access
PDF file
MVMihaela Valcovici
Mihaela Valcovici
MIMihai Sorin Iacob
Mihai Sorin Iacob
ASAbhinav Sharma
Abhinav Sharma
PAPAH ANA-MARIA
PAH ANA-MARIA
LMLucretia Marin-Bancila
Lucretia Marin-Bancila
Nilima Rajpal KundnaniNilima Rajpal Kundnani
Nilima Rajpal Kundnani
Background: Cardiovascular disorders, especially atherosclerosis, have been associated with allergic inflammation. In addition to traditional inflammatory responses, there is evidence that the development and instability of coronary artery plaque may be influenced by effector cells of allergic inflammation. This review examines the phases of allergic pathology, the immunological mechanisms of atherosclerosis, and the clinical link between allergic diseases (asthma, atopic dermatitis, allergic rhinitis, and food allergy) and cardiovascular disease (CVD), along with future therapeutic perspectives. Material and Method: A literature search was conducted in PubMed, Google scholar; ScienceDirect, Scopus, and studies published between 2014–2024 were taken into consideration. Keywords included allergic inflammation, eosinophils, mast cells, reactive oxygen species, atherosclerosis, Th2 cells, and cytokines. Epidemiological studies and review articles were included. Results: Emerging evidence suggests that allergic inflammation contributes to atherosclerosis through interconnected mechanisms such as eosinophil activation, reactive oxygen species production, mast cell degranulation, and endothelial dysfunction. Th2-driven immune responses, which are mediated by cytokines such as IL-4, IL-5, and IL-13, as well as eosinophil activity and mast cell degranulation, play a crucial role in vascular inflammation and plaque progression. Additionally, changes in lipid metabolism contribute to this process. Epidemiological studies support this connection, indicating that patients with chronic allergic conditions such as asthma, allergic rhinitis, food allergy, and atopic dermatitis experience increased cardiovascular morbidity. However, most current data are observational, and our understanding of the underlying mechanisms in humans remains limited, often relying on insights gained from preclinical models. Conclusions: A potential mechanism for cardiovascular risk is suggested by the interaction between atherosclerosis and allergic inflammation. Promising alternatives for treating allergic inflammation and cardiovascular issues include novel treatments like cytokine inhibitors, mast cell stabilizers, and biologics that target certain pathways. Further research is necessary to see whether concentrating on allergy pathways could lead to innovative treatments for cardiovascular disorders or vice versa.

9 April 2025 in Ultraschall in der Medizin - European Journal of Ultrasound
Verified
Journal Article
Open access
PDF file
CACamilla Aakjær Andersen
Camilla Aakjær Andersen
TLThomas Løkkegaard
Thomas Løkkegaard
LNLeizl Joy Nayahangan
Leizl Joy Nayahangan
HEHazel Edwards
Hazel Edwards
MIMihai Sorin Iacob
Mihai Sorin Iacob
CJChristian Jenssen
Christian Jenssen
Point-of-care ultrasound (PoCUS) has found its way into primary care in some, but not all, European countries. A prerequisite for achieving Europe-wide comparable diagnostic reliability of PoCUS performed by primary care physicians is high-quality training that is limited to relevant, frequently encountered PoCUS applications that are easy to learn and master. A European Federation of Societies for Ultrasound in Medicine (EFSUMB) task force performed a brainstorming exercise to identify all possible ultrasound examinations that could be performed in primary care. A 3-stage Delphi process was launched. The Delphi panelists were 95 primary care physicians from 28 European countries with more than 2 years of experience using and teaching ultrasound. Solely focusing on the complexity of performing PoCUS, the panelists reduced the brainstorming list in a stepwise manner to a basic core curriculum intended for primary care frontline physicians including 40 diagnostic PoCUS examinations within 13 different anatomical areas and no ultrasound-guided procedures. A 75% cut-off was used for agreement. Despite the great heterogeneity of the Delphi panel representing different views and contexts from across Europe, kappa statistics showed substantial or moderate agreement across Delphi rounds 2 and 3 for 85% of the 40 diagnostic PoCUS applications. The results of this study offer guidance for EFSUMB to establish training recommendations for a basic core curriculum that can be adapted to the needs of different regions of Europe and thus create a basis for PoCUS to become a reliable diagnostic tool in primary care across Europe, based on common quality standards.

29 October 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
MIMihai Sorin Iacob
Mihai Sorin Iacob
Nilima Rajpal KundnaniNilima Rajpal Kundnani
Nilima Rajpal Kundnani
ASAbhinav Sharma
Abhinav Sharma
ISIACOB ANDREI SORIN
IACOB ANDREI SORIN
ADANCA RALUCA DINU
ANCA RALUCA DINU
Simona DrãganSimona Drãgan
Simona Drãgan
Background: Focused cardiac ultrasound (FOCUS) can augment the cardiac exam in primary care but is operator-dependent. We evaluated the diagnostic performance of artificial intelligence-assisted FOCUS (AI-FOCUS) performed by family physicians against cardiologist-performed echocardiography. Methods: This research is a prospective cross-sectional study in primary care; family physicians performed conventional FOCUS and AI-FOCUS, with cardiologist-performed echocardiography within 24 h as the reference standard. The primary outcomes were accuracy, sensitivity/specificity, and agreement (κ). Results: AI-FOCUS achieved 94.33% accuracy (95% CI 93.15–95.35), 89.91% sensitivity, and 96.49% specificity, with excellent agreement compared to cardiologists (κ = 0.88). Among the confirmed abnormalities (32.9% of participants), valvular disease was most frequent (42%), followed by reduced LVEF < 50% (28%) and pericardial effusion (12%). In multivariable analysis, AI-assisted LVEF < 50% (OR = 6.05, p < 0.0001) and valvular abnormalities (OR = 4.05, p < 0.0001) were strong predictors of cardiac pathology. Conclusions: AI-FOCUS performed by trained family physicians showed high diagnostic accuracy and excellent agreement with blinded cardiologist-performed echocardiography for detecting LVEF < 50%, screening-level valvular abnormalities, and pericardial effusion, supporting its use for early detection and triage in primary care. Its ease of use and reproducibility suggest value in settings with limited access to cardiology.